CoChat

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

Open access

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) and internet-based cognitive behavioral therapy (ICBT) are recommended treatments of social anxiety disorder (SAD), and often combined, but their effects on monoaminergic signaling are not well understood. In this multi-tracer positron emission tomography (PET) study, 24 patients with SAD were randomized to treatment with escitalopram+ICBT or placebo+ICBT under double-blind conditions. Before and after 9 weeks of treatment, patients were examined with positron emission tomography and the radioligands [ 11 C]DASB and [ 11 C]PE2I, probing the serotonin (SERT) and dopamine (DAT) transporter proteins respectively. Both treatment combinations resulted in significant improvement as measured by the Liebowitz Social Anxiety Scale (LSAS). At baseline, SERT-DAT co-expression was high and, in the putamen and thalamus, co-expression showed positive associations with symptom severity. SERT-DAT co-expression was also predictive of treatment success, but predictor-outcome associations differed in direction between the treatments. After treatment, average SERT occupancy in the SSRI + ICBT group was >80%, with positive associations between symptom improvement and occupancy in the nucleus accumbens, putamen and anterior cingulate cortex. Following placebo+ICBT, SERT binding increased in the raphe nuclei. DAT binding increased in both groups in limbic and striatal areas, but relations with symptom improvement differed, being negative for SSRI + ICBT and positive for placebo + ICBT. Thus, serotonin-dopamine transporter co-expression exerts influence on symptom severity and remission rate in the treatment of social anxiety disorder. However, the monoamine transporters are modulated in dissimilar ways when cognitive-behavioral treatment is given concomitantly with either SSRI-medication or pill placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-022-02187-3

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Whole sample pre-treatment SERT and DAT binding. Left panel shows serotonin transporter non-displaceable binding potential pre treatment and the rightpanel shows non-displaceable binding potential for the dopamine transporter.
Fig. 1 Whole sample pre-treatment SERT and DAT binding. Left panel shows serotonin transporter non-displaceable binding potential pre treatment and the rightpanel shows non-displaceable binding potential for the dopamine transporter.CC BY · PubMed Central
Fig. 2 PET results from the SSRI + ICBT group. Regions where significant positive associations between SERT occupancy and symptom improvement were detected, i.e., the left anterior cingulate, right nucleus accumbens and left putamen.
Fig. 2 PET results from the SSRI + ICBT group. Regions where significant positive associations between SERT occupancy and symptom improvement were detected, i.e., the left anterior cingulate, right nucleus accumbens and left putamen.CC BY · PubMed Central
Fig. 3 Scatterplots of significant group differences in associations between symptom improvement, as measured with the Liebowitz Social Anxiety Scale (LSAS), and the percentage change in DAT BPND in the left nucleus accumbens (L NAcc), right NAcc (R NAcc) and left thalamus. Clusters of significant voxels (PFWE < 0.05) shown overlaid on a standard anatomical brain template.
Fig. 3 Scatterplots of significant group differences in associations between symptom improvement, as measured with the Liebowitz Social Anxiety Scale (LSAS), and the percentage change in DAT BPND in the left nucleus accumbens (L NAcc), right NAcc (R NAcc) and left thalamus. Clusters of significant voxels (PFWE < 0.05) shown overlaid on a standard anatomical brain template.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 2

  1. First MB, Spitzer RL, Gibbon MB, Williams J. Structured clinical interview for DSM-IV axis i disorders – non-patient edition. New York: New York State Psychiatric Institute. 1997.
  2. Clark DM, Wells A. A cognitive model of social anxiety. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, editors. Social phobia: diagnosis, assessment and treatment. Guilford Press: New York, NY, 1995, pp 69–93.

Cited by

See all 14

Metadata

Authors
Hjorth, O., Frick, A., Gingnell, M., Engman, J., Björkstrand, J., Faria, V., Alaie, I., Carlbring, P., Andersson, G., Jonasson, M., Lubberink, M., Antoni, G., Reis, M., Wahlstedt, K., Fredrikson, M., & Furmark, T.
Affiliations
  • Uppsala University (SE)
  • Lund University (SE)
  • Boston Children's Hospital (US)
  • Stockholm University (SE)
  • Linköping University (SE)
Corresponding author
Hjorth, Olof
Venue
Translational Psychiatry
Published
2022-10-07
Volume
12
Issue
1
Pages
436-436
ISSN
2158-3188 (ISSN-L)
OpenAlex
W4302774148
Cited by
13
References
79
Citations by year
2026: 4 · 2025: 6 · 2024: 1 · 2023: 2
FWCI
2.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Vetenskapsrådet
  • Hjärnfonden
  • Riksbankens Jubileumsfond
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
social anxiety disorder, serotonin transporter, dopamine transporter, escitalopram, internet-based cognitive behavioral therapy, combined psychotherapy and pharmacotherapy, monoaminergic signaling, treatment response prediction, [11C]DASB, [11C]PE2I, nucleus accumbens, putamen, thalamus, raphe nuclei, striatum
MeSH terms
Phobia, Social, Escitalopram, Brain, Dopamine, Humans, Serotonin, Cognitive Behavioral Therapy, Selective Serotonin Reuptake Inhibitors, Dopamine Plasma Membrane Transport Proteins, Serotonin Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy. https://app.cochat.ai/papers/10.1038/s41398-022-02187-3
The paper
Hjorth, O., Frick, A., Gingnell, M., Engman, J., Björkstrand, J., Faria, V., Alaie, I., Carlbring, P., Andersson, G., Jonasson, M., Lubberink, M., Antoni, G., Reis, M., Wahlstedt, K., Fredrikson, M., & Furmark, T. (2022). Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy. Translational Psychiatry. https://doi.org/10.1038/s41398-022-02187-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.